CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
Endocrinol Metab. 2021;36(2):413-423.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.906

Excel Download

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
Endocrinology and Metabolism. 2021;36(2):413-423   Crossref logo
Link1 Link2 Link3

Absolute Eosinophil Count May be an Optimal Peripheral Blood Marker to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors: A Retrospective Analysis.
. 2021;   Crossref logo
Link1 Link2

Absolute Eosinophil Count May be One of the Most Optimal Peripheral Blood Markers to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors.
. 2021;   Crossref logo
Link1 Link2

OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
Journal of the Endocrine Society. 2020;4(Supplement_1):   Crossref logo
Link1 Link2

Absolute Eosinophil Count May be an Optimal Peripheral Blood Marker to Identify Risk of Immune-Related Adverse Events in Advanced Malignant Tumors Treated with PD-1/PD-L1 Inhibitors: A Retrospective Analysis.
. 2021;   Crossref logo
Link1 Link2

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
Cancers. 2021;13(21):5465   Crossref logo
Link1

Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials
Annals of Oncology. 2019;30:v527-v528   Crossref logo
Link1 Link2 Link3

Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital
European Journal of Inflammation. 2022;20:1721727X2210915   Crossref logo
Link1 Link2 Link3

Immune-related adverse events associated with PD-1/PD-L1 Inhibitors used as first-line treatment for advanced non-small cell lung cancer: a Bayesian network meta-analysis of randomized clinical trials
. 2021;   Crossref logo
Link1 Link2

CNS Radiation-Related Adverse Events in Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors
International Journal of Radiation Oncology*Biology*Physics. 2017;99(2):S150-S151   Crossref logo
Link1 Link2